Pinealon (EDR) Tripeptide: Research Guide for 2026

Search for "pinealon" and you will find a strange gap. Dozens of comparison pages rank reasonably well for "pinealon vs semax" or "pinealon vs epithalon," yet the compound's own name barely shows up in the top results anywhere. That is backwards for a peptide with actual published literature behind it. This guide is our attempt to close that gap: what Pinealon (EDR) actually is, what the Khavinson group's published work reports, and where the evidence stops.

Pinealon is a synthetic tripeptide with the sequence glutamate, aspartate, arginine, shortened to EDR using single letter amino acid codes. It came out of the peptide bioregulator research program run by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. Published papers from that group describe EDR entering cell nuclei and interacting with specific DNA sequences, plus effects in central nervous system cell culture and animal models. We are covering both here, along with the honest limitation that almost none of this work has been replicated outside the group that produced it. Pinealon is available for laboratory research only.

!Pinealon tripeptide structure

What Pinealon Is

Start with the chemistry, since it is simple and often skipped over. Pinealon is glutamic acid, aspartic acid, and arginine linked in that order: Glu-Asp-Arg, or EDR. Three amino acids. No branching, no modified residues, nothing exotic. That size matters for a lot of what follows, because a tripeptide behaves very differently from a 30 or 40 residue peptide in terms of stability, membrane crossing, and how easily it gets degraded once it is in solution.

The compound sits inside a larger family Khavinson's group calls peptide bioregulators. Each one is a short peptide, usually two to four amino acids, matched conceptually to a tissue of origin. Epithalon (Ala-Glu-Asp-Gly, AEDG) is the pineal gland peptide. Cortagen targets cerebral cortex tissue. Vesugen is associated with vascular tissue. Pinealon's assigned tissue is the central nervous system broadly, not the pineal gland specifically, despite the name's obvious echo of "pineal." That naming choice trips people up. Epithalon is the pineal-derived one; Pinealon is the CNS-targeted one, and the two get confused in casual write-ups more often than you'd expect.

Where does the idea come from in the first place? Khavinson's rationale traces back to older work on tissue extracts, Epithalamin among them, a polypeptide preparation derived from bovine pineal tissue that was studied in Russian aging research going back decades. The theory was that pineal and CNS tissue contain naturally occurring short peptides that carry some kind of regulatory signal specific to that tissue, and that synthesizing short fragments matching those sequences might reproduce part of the effect without needing a crude tissue extract. Pinealon is one of several synthetic tripeptides built on that premise, positioned as a cleaner, better-defined alternative to whole-extract preparations like Epithalamin.

Whether that theoretical framework holds up is a separate question from whether the specific experimental findings on Pinealon are real and worth examining. We think they are worth examining. But it is fair to flag upfront that the "tissue-specific regulatory peptide" idea is Khavinson's interpretive lens on the data, not an independently established mechanism accepted broadly across peptide biology. Keep that separation in mind as we go through the actual findings.

Key Research Findings at a Glance

• Fedoreyeva et al. showed fluorescently labeled EDR penetrates into the nucleus of HeLa cells and binds specific DNA sequences with measurable specificity, using fluorescence quenching assays (PMID 22117547).
• In a rat model of prenatal hyperhomocysteinemia, Pinealon reduced reactive oxygen species and necrotic cell counts in offspring cerebellum neurons, and improved offspring spatial learning (PMID 22567179).
• EDR stimulated serotonin expression in aging brain cortex cell cultures, with molecular docking data suggesting direct regulation of the tryptophan hydroxylase gene (PMID 24909721).

The Peptide Bioregulator Framework

Here is the hypothesis in plain terms. Khavinson's group proposes that ultrashort peptides, two to four amino acids, can enter a cell nucleus and physically interact with DNA at specific sequence motifs, functioning as a kind of epigenetic switch that turns certain genes up or down. This is a stronger and more specific claim than "peptides can affect gene expression somehow." It says these particular short sequences bind particular DNA regions and that binding has downstream transcriptional consequences.

That is a hypothesis, not settled biology. Short peptide to DNA interaction of this kind is not part of mainstream molecular biology curricula, and most gene regulation research focuses on transcription factors, which are considerably larger proteins with well-characterized DNA-binding domains. A three or four amino acid chain interacting sequence-specifically with double-stranded DNA is an unusual claim on its face. It is not impossible. Short peptide-nucleic acid interactions do exist in nature (certain antimicrobial peptides, some viral proteins use short motifs to engage nucleic acids), but the specificity and functional consequence Khavinson's group describes for compounds like EDR is a much bigger ask.

So what is the actual supporting evidence? The clearest piece comes from Fedoreyeva and colleagues, who used fluorescently labeled versions of several bioregulator peptides, including EDR, and tracked their movement into HeLa cell nuclei under a microscope. They then ran fluorescence quenching experiments to test whether the peptides bound labeled DNA oligonucleotides in vitro, and found that binding strength varied depending on the specific nucleotide sequence tested. EDR showed a binding preference for CAG-containing sequences, distinct from the binding pattern shown by Epithalon or bronchogen in the same experiment. That specificity, different peptides binding different sequence motifs, is the strongest piece of evidence for the "sequence-specific interaction" part of the hypothesis. It doesn't prove a functional transcriptional consequence on its own, but it is a real, replicable-in-principle biochemical observation, not just a claim.

What about the mechanism connecting nuclear DNA binding to the downstream effects reported in cell cultures and animal models? That is where things get thinner. The gene expression changes Khavinson's group reports (serotonin pathway genes, antioxidant response genes, and others depending on the paper) are consistent with the DNA-binding hypothesis but don't prove causation from it. Correlation between "peptide is present" and "certain genes changed expression" doesn't establish that the peptide caused the change through direct DNA binding specifically, as opposed to some downstream signaling cascade the peptide triggered by another route entirely. The docking study we cover below is a computational prediction, not a direct biochemical demonstration of binding at that exact promoter site. Treat the whole framework as a working hypothesis with some genuinely interesting supporting data, not a proven mechanism.

One earlier paper from the group, published in Rejuvenation Research in 2011, is worth calling out because it directly tests the cell to genome interaction claim rather than just describing downstream effects. Khavinson, Ribakova, Kulebiakin, and colleagues found that Pinealon reduced reactive oxygen species accumulation and necrotic cell death, dose dependently, across three different cell types: cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells. They also tracked ERK 1/2 activation and cell cycle progression, and found that the antioxidant effect saturated at lower peptide concentrations while cell cycle modulation kept scaling at higher doses. Two effects with two different dose response curves is the kind of detail that suggests two separate mechanisms rather than one effect wearing two hats, and the authors used exactly that logic to argue Pinealon interacts directly with the cell genome on top of its antioxidant activity (PMID 21978084).

What the Published Research Reports

We reviewed the primary papers behind the claims most commonly repeated about Pinealon online, and it is worth being specific about which model system produced which finding, since a lot of secondary coverage blurs cell culture data into animal data into vague "studies show" language. Three papers carry most of the weight here.

The DNA Interaction Hypothesis

Fedoreyeva, Kireev, Khavinson, and Vanyushin published the foundational nuclear-penetration paper in Biochemistry (Moscow) in 2011. Working in HeLa cells (a human cervical cancer cell line, not neuronal tissue, which is a detail some secondary sources gloss over), they incubated cells with fluorescein-labeled short peptides, EDR among them, and observed fluorescence accumulating in the cytoplasm, the nucleus, and the nucleolus. That confirmed the peptides physically get inside the nucleus. The team then ran separate in vitro binding assays using fluorescence quenching to measure how strongly each peptide interacted with different single and double stranded DNA oligonucleotide sequences.

The result: EDR, along with epithalon and testagen, showed preferential binding to CAG-containing sequences, while bronchogen preferred CTG sequences. The peptides also appeared able to discriminate methylated versus unmethylated cytosine at CNG sites, which the authors flagged as potentially relevant to epigenetic regulation, since CNG methylation status affects gene expression in eukaryotic cells (PMID 22117547). This is a HeLa cell and in vitro biochemistry paper. It says nothing directly about neurons, and nothing about live animals. What it does establish, reasonably convincingly, is that this class of short peptide can enter nuclei and bind DNA with some sequence specificity. That is the base the rest of the framework builds on.

Is that enough to call it settled? No. One paper, one lab, one cell line, no independent replication we could locate in the broader literature. The finding is specific enough (measurable quenching constants, distinct binding patterns across different peptides) that it doesn't read like vague hand-waving, and the method (fluorescence quenching for nucleic acid binding) is a standard technique used elsewhere in biochemistry. Still, "used a standard technique" and "independently confirmed by another group" are different bars, and only the first one is cleared here.

The functional side of the hypothesis, that this DNA binding actually drives the neuroprotective and gene-expression effects described elsewhere in the literature, comes from Khavinson, Lin'kova, Tarnovskaya, and colleagues, published in the Bulletin of Experimental Biology and Medicine in 2014. Working in aging brain cortex cell cultures, they found that EDR and a related dipeptide, Lys-Glu-Asp, stimulated serotonin expression. Using molecular docking, a computational method for predicting how a small molecule fits against a target structure, they identified a CCTGCC sequence within the tryptophan hydroxylase gene (the enzyme that makes the rate-limiting step in serotonin synthesis) as a plausible binding site complementary to these peptides (PMID 24909721). The authors describe this as epigenetic regulation of serotonin synthesis with both neuroprotective and geroprotective (aging-related) relevance.

Two things worth flagging about that paper. First, "molecular docking suggests a binding site" is a prediction, not direct structural confirmation via something like crystallography or a gel shift assay. It is a reasonable first step, not a final answer. Second, aging cell cultures are a specific and somewhat unusual model system; the serotonin finding is interesting but narrow, and it hasn't (to our knowledge) been extended to a broader panel of aging-related genes to see how general the effect is.

The third major paper moves out of cell culture entirely and into an animal model. Arutjunyan, Kozina, Stvolinskiy, Bulygina, Mashkina, and Khavinson published a study in the International Journal of Clinical and Experimental Medicine in 2012 examining Pinealon in pregnant rats with diet-induced hyperhomocysteinemia (elevated homocysteine caused by excess dietary methionine, a model used to study prenatal metabolic stress and its effects on offspring neurodevelopment). Pinealon administration to the pregnant dams was associated with improved spatial orientation and learning ability in the offspring, along with reduced reactive oxygen species accumulation and fewer necrotic cells in cerebellum neurons isolated from the offspring (PMID 22567179). The authors describe the finding as consistent with earlier in vitro neuroprotective data from the same research group, which is an honest way of saying: this fits our existing hypothesis, but it is also the same group building on its own prior work rather than an outside lab testing the claim independently.

A fourth paper worth mentioning briefly, since it turns up in the reference list, looked at organotypic pineal cell culture rather than cortical or cerebellar neurons. Khavinson, Linkova, Chalisova, and colleagues tested several bioregulator peptides on pinealocyte cultures from rat pineal glands and found that EDR did not affect the apoptosis marker AIF, unlike Epithalon's dipeptide relative Lys-Glu-Asp, which showed different signaling effects entirely. It is a useful negative-ish result: EDR isn't doing everything all the bioregulator peptides do, which cuts against the idea that these compounds are interchangeable and supports the tissue-specificity part of Khavinson's framework (PMID 22803060). A more recent 2020 paper in Molecules revisited the DNA interaction hypothesis specifically in the context of Alzheimer's disease pathogenesis, proposing a mechanism by which EDR peptide binding to gene promoter regions could influence protein synthesis pathways relevant to neurodegeneration (PMID 33396470). That paper is theoretical and mechanism-focused rather than new experimental data, but it shows the line of thinking is still active.

Research Considerations for 2026

For researchers considering Pinealon as a subject of study, several practical points stand out. First, the compound is a tripeptide, which means it is small enough to potentially cross membranes more readily than larger peptides, but it is also more susceptible to enzymatic degradation in solution. Stability considerations matter for experimental design, and researchers should verify peptide integrity under their specific buffer and temperature conditions.

Second, the evidence base is narrow. Almost all published work comes from a single research group, and independent replication is lacking. That doesn't invalidate the findings, but it does mean researchers should treat the literature with appropriate caution and design experiments that can stand on their own merits. Third, the dose-response data from the 2011 Rejuvenation Research paper suggests that different concentrations may produce different effects, which is a useful reminder that dose selection is not trivial with this compound.

Researchers planning studies with Pinealon may find the peptide reconstitution calculator helpful for preparing accurate working solutions, and the stability calculator for assessing storage conditions. For those comparing Pinealon to other bioregulator peptides, the peptide glossary provides a useful reference for terminology.

Related Research Compounds

Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.

Browse Full Catalog →